While Big Pharma pours billions into obesity drug R&D, a new biotech startup is taking a shortcut: licensing ready-to-go therapies from China. Kailera Therapeutics, launched with $400 million from Bain Capital, Atlas Venture, and RTW Investments, is fast-tracking four obesity drugs developed by Jiangsu Hengrui — one of China’s pharmaceutical heavyweights.
The playbook? Bypass years of early-stage research. “We saw next-gen GLP-1 therapies that could leapfrog existing options,” says Dr. Amir Zamani, Bain’s life sciences partner who spearheaded the deal. One injectable candidate from Hengrui showed 59% of patients losing 20 %+ body weight in Phase II trials, with mild side effects. Even more promising: two of the licensed drugs are pills, a potential game-changer in a market currently dominated by injectables.
Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram
With global obesity drug sales projected to hit $131 billion by 2028, Kailera aims to move fast. Leading the charge is biotech veteran Ron Renaud, who’s sold three companies for a combined $16 billion. “We likely have the most advanced and diverse weight-loss pipeline outside Big Pharma,” he says. The goal is to bring the first drug to market by 2030 — a rapid timeline thanks to Hengrui’s head start.
China’s rise as a pharmaceutical R&D hub is reshaping the biotech map. Over a third of molecules licensed by Western firms now originate there. U.S. firms have spent $8.1 billion since 2020 licensing Chinese-developed drugs — a stark contrast to just $536 million in the previous five years.
Kailera is betting this east-west fusion can deliver blockbuster results. With 100 million obese adults in the U.S. alone — not to mention global demand — the addressable market is massive. “This isn’t a one-drug race,” Renaud says. “It’s going to take an entire arsenal.”
To prep for launch, Kailera has added top-tier talent: Scott Wasserman, former cardiovascular lead at Amgen, is chief medical officer; Jamie Coleman, who led Zepbound’s commercial rollout at Lilly, now heads marketing.
Whether Kailera becomes the next independent giant or is eventually snapped up by Big Pharma, as Renaud’s previous ventures were, it’s already a standout in the white-hot weight-loss drug race.
